Fetal diagnosis and therapy
-
To examine the feasibility of fetal RHD genotyping at 11-13 weeks' gestation from analysis of circulating cell-free fetal DNA (ccffDNA) in the plasma of RhD negative pregnant women using a high-throughput robotic technique. ⋯ The findings demonstrate the feasibility and accuracy of non-invasive fetal RHD genotyping at 11-13 weeks with a high-throughput technique.